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a b s t r a c t 
A majority of small cell lung cancer (SCLC) cells lack a metastasis suppressor, tetraspanin CD9, and CD9
expression promotes their apoptosis. By a proteomics-based approach, we compared an SCLC cell line
with its CD9 transfectant and found that a calcium-binding neuronal protein, calretinin, is upregulated
in CD9-positive SCLC cells. Ectopic or anticancer drug-induced CD9 expression upregulated calretinin,
whereas CD9 knockdown down-regulated calretinin in SCLC cells. When calretinin was knocked down,
CD9-positive SCLC cells revealed increased Akt phosphorylation and decreased apoptosis. These results
suggest that CD9 positively regulates the expression of calretinin that mediates proapoptotic effect in
SCLC cells. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY license. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Small cell lung cancer (SCLC) is highly malignant lung tumor that
spreads early throughout the body. It is characterized by neuroen-
docrine features such as neuropeptide production and N-CAM ex-
pression [ 1 ]. At diagnosis in most cases, SCLC has already metasta-
sized to regional lymph nodes and distant organs including brain,
bone, liver, and adrenal gland, thus excluding the possibility of surgi-
cal resection. Currently, standard treatment against extended SCLC is
chemotherapy including cisplatin and etoposide [ 2 ]. Despite its high
sensitivity to these anticancer drugs, SCLC rapidly develops recurrent
tumors locally and at the distant organs. Such malignant phenotype is
at least partially caused by acquired resistance to apoptotic cell death
[ 3 ]. Elucidation of its mechanisms is necessary to improve outcomeAbbreviations: SCLC, small cell lung cancer; NSCLC, nonsmall cell lung cancer; PARP, 
poly(ADP-ribose)polymerase; PMF, peptide mass ﬁngerprinting; MALDI-TOF, matrix- 
assisted laser desorption / ionization time-of-ﬂight; RT-PCR, reverse transcription-PCR; 
KO, knockout 
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2211-5463 c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe
http://dx.doi.org/10.1016/j.fob.2013.04.005 of chemotherapy, but little has been clariﬁed. 
Tetraspanins are a family of membranous proteins that has char-
acteristic structure spanning the membrane four times. Through as-
sociation with other functional proteins including integrins, growth
factor receptors, membrane proteases, and intracellular signaling
molecules, tetraspanins organize multiprotein complexes at the
tetraspanin-enriched microdomain (TEM) and regulate cell adhesion,
migration, and survival [ 4 , 5 ]. Among 33 members in humans, CD9 and
CD82 are known as a metastasis suppressor of solid tumors. Clinical
and pathological ﬁndings suggest that decreased expressions of these
tetraspanins are associated with progression of cancers of breast, pan-
creas, colon, and esophagus, and nonsmall cell lung cancer (NSCLC)
and thus with poor prognosis [ 6 , 7 ]. 
We have shown that, among tetraspanins, CD9 is selectively ab-
sent in a majority of SCLC lines and SCLC tissues in contrast to NSCLC
which frequently expresses CD9, and that ectopic expression of CD9
in SCLC cells suppresses integrin β1-dependent cell motility [ 8 ] and
promotes apoptotic cell death through attenuation of PI3K / Akt sig-
naling [ 9 ]. These results suggest that the absence of CD9 contributes
to highly malignant phenotype of SCLC. We also found that CD9 ex-
pression is induced and cell motility is decreased when SCLC cells
are exposed to cisplatin or etoposide [ 10 ]. In the present study, we
compared an SCLC cell line with its CD9 transfectant by a proteomics-
based approach and found that a calcium-binding neuronal protein,an Biochemical Societies. Open access under CC BY license.
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 alretinin, is upregulated in CD9-positive SCLC cells. We also show 
hat calretinin mediates apoptotic cell death of SCLC. 
. Materials and methods 
.1. Cell lines 
OS1, OS2-RA, and OS3-R5 were SCLC cell lines established in our 
aboratory, and their biological properties were previously character- 
zed [ 8 ]. SCLC lines, OC10 and CADO LC6, a lung adenocarcinoma cell 
ine, CADO LC9, and a mesothelioma cell line, OC-(MT)37, were pro- 
ided by Osaka Medical Center for Cancer and Cardiovascular Diseases 
Osaka, Japan) [ 11 ]. An SCLC line, SBC-3, and its chemoresistant sub- 
ine, SBC-3 / CDDP, were kindly provided by Dr. K. Kiura (Okayama Uni- 
ersity, Okayama, Japan) [ 10 ]. SCLC cell lines, NCI-H69, NCI-N231, and 
CI-H209, a lung adenocarcinoma line, A549, and pleural mesothe- 
ioma lines, NCI-H226, NCI-H2452, NCI-H28, and MSTO-211H, were 
urchased from American Type Culture Collection (Rockville, MD). 
 lung squamous cell carcinoma line, HARA, was a kind gift from 
r. H. Iguchi (Kyusyu Cancer Center, Fukuoka, Japan). All cell lines 
ere maintained in RPMI 1640 medium supplemented with 10% heat- 
nactivated FBS, 100 U / ml penicillin, and 100 μg / ml streptomycin. 
.2. Antibodies and reagents 
Mouse anti-CD9 mAb (MM2 / 57), anti-poly(ADP- 
ibose)polymerase (PARP) mAb (42 / PARP), and anti- β-actin 
Ab (C4) were purchased from Biosource, BD Biosciences, and 
anta Cruz Biotechnology, respectively. Mouse anti-CD9 mAb (72F6) 
as purchased from Novocastra. Goat anti-calretinin polyclonal 
b (AB1550) and rabbit anti-calretinin polyclonal Ab (DC8) were 
urchased from Chemicon International and Zymed Laboratories, 
espectively. Rabbit anti-cleaved PARP (Asp214) mAb (D64E10), 
nti-phospho-Akt (Ser473) mAb (D9E), and anti-Akt polyclonal Ab 
ere purchased from Cell Signaling Technology. Cisplatin (CDDP) 
as provided by Nippon Kayaku Co. (Tokyo, Japan). 
.3. Flow cytometry 
Cells (10 4 ) were incubated with 10 μg / ml primary mouse mAbs 
nd labeled with FITC-conjugated goat anti-mouse immunoglobulin 
Biosourece International). Normal mouse IgG was used as a control. 
tained cells were analyzed on a FACScan (Becton Dickinson). 
.4. cDNA and small interfering RNA (siRNA) transfection 
Establishment of stable CD9-, NAG-2-, and mock-transfectants 
f OS3-R5 was previously described [ 8 , 9 ]. Cells were transfected 
ith 40 nM cocktail siRNAs against human CD9 (No. SHF27A-0631; 
-Bridge International) or human calretinin (No. SHF27A-0981; B- 
ridge International), or negative control cocktail RNAs (No. S30C- 
126; B-Bridge International) using LipofectAMINE 2000 Reagent (In- 
itrogen). 
.5. Two-dimensional electrophoresis (2-DE) and mass spectrometry 
nalysis 
Proteins were extracted from cells with the Complete Mammalian 
roteome Extraction Kit (Calbiochem, Darmstadt, Germany). For 2- 
E, isoelectric focusing (IEF) was performed using the PROTEAN IEF 
ell (Bio-Rad laboratories) according to the manufacturer’s instruc- 
ions. Extracted proteins were reconstituted in a rehydration buffer 
7 M urea, 2 M thiourea, 4% CHAPS, 2 mM tributylphosphine (TBP), 
.0002% bromophenol blue (BPB), 0.2% Bio-lyte ampholyte 4–7) and 
pplied to ReadyStrip TM IPG strips (11 cm, pH 4–7). IEF was run for 
5,000 Vh. Two-dimensional electrophoresis was carried out in 10% 
is–Tris Criterion TM XT Precast gels. After staining with the Silver Stain MS Kit (Wako Pure Chemical Industries, Osaka, Japan), the gels 
were captured by transmission scanning and analyzed with Image 
Master 5.0 (Amersham Biosciences). Following analysis, selected pro- 
tein spots were manually excised from the gels and digested with 
trypsin (Promega) according to published procedures [ 12 ]. All pep- 
tide mass ﬁngerprinting (PMF) spectra were obtained by using an 
ultraﬂex TOF / TOF matrix-assisted laser desorption / ionization time- 
of-ﬂight (MALDI-TOF) mass spectrometer (Bruker Daltonics, Bremen, 
Germany). 
2.6. Database search 
PMF data were searched with Mascot software (Matrix Science, 
London, UK) against NCBInr or Swiss-Prot databases. Protein database 
searching was performed with following parameters: Homo sapiens , 
maximum of one missed, cleavage by trypsin, monoisotopic masse 
value, charge state of 1 + , allowing a mass tolerance of 100 ppm, and 
carbamidomethyl modiﬁcation of cysteine. Protein scores of > 64 in- 
dicate identity or extensive homology ( P < 0.05) and were considered 
signiﬁcant. 
2.7. Reverse transcription-PCR (RT-PCR) 
One microgram of total RNA was reversely transcribed with a 
cDNA synthesis kit (Invitrogen) using random hexamers. The ther- 
mal cycling parameters were 30 cycles of 40 s at 94 ◦C, 40 s at 60 ◦C, 
and 90 s at 72 ◦C for CD9 and 30 cycles of 30 s at 94 ◦C, 30 s at 60 ◦C, and
90 s at 72 ◦C for calretinin. We conﬁrmed that these variables yielded 
ampliﬁcation of template DNAs within a linear range. The sequences 
of upstream and downstream oligonucleotide primers for CD9 was 
previously described [ 8 ]. Upstream and downstream oligonucleotide 
primers used for calretinin were 5 ′ -GGAAGCACTTTGACGCAGACG-3 ′ 
and 5 ′ -CTCGCTGCAGAGCACAATCTC-3 ′ , respectively. 
2.8. Immunoprecipitation and immunoblotting 
Cells were lysed in lysis buffer containing 1% Brij 99, 25 mM 
HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 2 mM phenylmethylsul- 
fonyl ﬂuoride, 10 μg / ml aprotinin, and 10 μg / ml leupeptin. Whole cell 
lysates or immunoprecipitates with anti-CD9 mAb (MM2 / 57) were 
separated by 10% SDS-PAGE under nonreducing conditions for CD9 
or under reducing conditions for the other proteins. After transfer 
to Immobilon-P membranes (Millipore), immunoblotting was per- 
formed with primary Abs followed by peroxidase-conjugated sec- 
ondary Abs. Immunoreactive bands were visualized with a chemilu- 
minescent reagent (PerkinElmer). 
2.9. Immunohistochemistry 
A human SCLC tissue array was purchased from US Biomax Inc. It 
contained small cell carcinoma tissues from 30 individuals and normal 
tissues from three individuals. Each specimen was represented by two 
cores from different tissue spots. After antigen retrieval, inactivation 
of endogenous peroxidase, and blockade of non-speciﬁc reaction, the 
tissue microarray sections were stained with anti-CD9 mAb (72F6) 
or anti-calretinin Ab (DC8), followed by incubation with biotinylated 
goat anti-mouse and rabbit IgG Ab and streptavidin-conjugated per- 
oxidase. These were counterstained with Mayer’s hematoxylin [ 10 ]. 
Specimens were regarded as positive when staining was observed in 
more than 30% of tumor cells on average. The signiﬁcance of associ- 
ation between CD9 staining and calretinin staining was evaluated by 
Fisher’s exact test. 
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Fig. 1. Comparative proteomic analysis of the parent and CD9-overexpressing SCLC cells. (A) The parent, mock transfectant, and CD9 transfectant of OS3-R5 were stained with 
anti-CD9 mAb, labeled with FITC-conjugated goat anti-mouse immunoglobulin, and analyzed on a FACScan ( Open histograms ). Closed histograms indicate staining with control IgG. 
(B) Representative 2-DE maps of OS3-R5 and its transfectants. Arrows 1–3 indicate protein spots selectively identiﬁed in OS3-R5-CD9 by mass spectrometry. 1 and 2, calretinin; 3, 
PA28 α. Images including the calretinin spots were enlarged in lower columns . (C) PMF spectra of spot 2 obtained by MALDI-TOF. Mass peaks, peptides of which were matched with 
human calretinin, are marked with numbers. (D) The matched peptides in panel (C) were indicated with bars, yielding 33% sequence coverage of calretinin. 
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Fig. 2. Co-expression of CD9 and calretinin in SCLC cells. (A) Total RNA was extracted 
from the parent, mock transfectant, and CD9 transfectant of OS3-R5 and analyzed for 
expressions of CD9 and calretinin by RT-PCR. β-Actin ampliﬁcation was used as the 
internal control ( left ). The parent, mock transfectant, NAG-2 transfectant, and CD9 
transfectants of OS3-R5 were lysed with 1% Brij 99 lysis buffer. Cell lysates were ana- 
lyzed for expressions of CD9 and calretinin by immunoblotting. Anti- β-actin blots were 
used as the internal control ( right ). (B) Total RNA was extracted from multiple SCLC 
and NSCLC cell lines and analyzed for expressions of CD9 and calretinin by RT-PCR. Ad, 
adenocarcinoma; Sq, squamous cell carcinoma. (C) An SCLC line OS1 ( left ) or a mesothe- 
lioma line NCI-H226 ( right ) was transfected with siRNAs against CD9 or control RNAs. 
Cell lysates were analyzed for expressions of CD9 and calretinin by immunoblotting. 
(D) Cell lysates of SCLC lines SBC-3 and SBC-3 / CDDP were analyzed for expressions of 
CD9 and calretinin by immunoblotting. 
2
o
i
i
O
2
c
p
t
w
C
w
m
t
Fig. 3. CD9 is not physically associated with calretinin. (A) Immunohistochemical 
staining of CD9 and calretinin in a double-positive specimen from an SCLC tissue mi- 
croarray. Insets show enlarged images of a part of sections. Bar, 50 μm. Signiﬁcant 
association between CD9 and calretinin expressions in the tissue microarray was eval- 
uated by Fisher’s exact test ( table ). (B) CD9 and calretinin in whole cell lysate (WCL) 
and in immunoprecipitates (IP) with anti-CD9 mAb or control IgG of OS3-R5-CD9 were 
immunoblotted (IB). Arrowheads indicate nonspeciﬁc binding of secondary Abs. .10. Mice 
The generation of CD9 knockout (KO) mice was described previ- 
usly [ 13 ]. These mice were backcrossed more than six generations 
nto the C57BL / 6J background. The mice were bred in a barrier facil- 
ty, and all animal procedures were performed in accordance with the 
saka University guidelines on animal care. 
.11. Apoptosis analysis 
Cells were transfected with siRNA against calretinin or negative 
ontrol RNAs. After 24 h, the cells were cultured in the absence or 
resence of CDDP in low-serum (0.1% FBS) RPMI 1640 for 48 h. Apop- 
otic cleavage of PARP [ 14 ] and decrease of Akt phosphorylation [ 9 ] 
ere analyzed by immunoblotting. Viable cells were quantiﬁed with 
ell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). Assays 
ere performed in triplicate cultures and values are expressed as 
ean ± SD. Statistical differences were determined by Student’s t - 
est. P < 0.05 was considered statistically signiﬁcant. 3. Results 
3.1. Identiﬁcation of proteins upregulated in OS3-R5-CD9 cells 
We previously established a CD9 ( −) SCLC cell line OS3-R5 and its 
CD9 transfectant OS3-R5-CD9 and revealed that the CD9 transfectants 
were less motile on ﬁbronectin [ 8 ] and revealed enhanced apoptosis 
in low-serum culture conditions [ 9 ]. To detect molecules that regu- 
late these changes, cell lysates of the parent, mock transfectant, and 
CD9 transfectant of OS3-R5 ( Fig. 1 A) were subjected to 2-DE, and pro- 
tein spots were visualized by silver stain of the gels. Spots selectively 
overexpressed in OS3-R5-CD9 were identiﬁed ( Fig. 1 B) and the corre- 
sponding proteins were analyzed by mass spectrometry. We repeated 
this experiment and found that two proteins, a calcium-binding pro- 
tein, calretinin, and a proteasome activator subunit 1, PA28 α, were 
reproducibly overexpressed in OS3-R5-CD9 cells ( Table S1 ). Fig. 1 C 
shows PMF spectra of spot 2 obtained by MALDI-TOF. Matched pep- 
tides were found to cover 33% of protein sequence of calretinin ( Fig. 
1 D). Based on the fact that SCLC has neuronal features, we further 
analyzed calretinin, which is a protein distributed in the nervous sys- 
tem. 
3.2. Co-expression of CD9 and calretinin in SCLC cells 
RT-PCR revealed that the calretinin gene was minimally tran- 
scribed in the parent and mock-transfected OS3-R5 cells, and that 
ectopic expression of CD9 promoted its transcription ( Fig. 2 A, left 
column ). To test the calretinin induction is speciﬁcally related to 
CD9, multiple CD9 transfectants and cells transfected with another 
tetraspanin NAG-2 were examined. As shown in Fig. 2 A, right column , 
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Fig. 4. Calretinin promotes apoptosis of CD9 ( + ) SCLC cells. (A) CD9 ( + ) / calretinin 
( + ) OS1 cells were transfected with siRNAs against calretinin or control RNAs and 
cultured in low-serum conditions in the absence or presence of 5 μM CDDP for 48 h. 
Cell lysates were analyzed for expressions of PARP (113 kD), phosphorylated Akt (p- 
Akt), total Akt, CD9, and calretinin by immunoblotting. Anti- β-actin blots were used as 
the internal control ( upper ). Viable cells were quantiﬁed with a cell counting kit ( lower ). 
* P < 0.01. (B) The parent and CD9 transfectant of OS3-R5 were cultured in low-serum 
conditions in the indicated concentrations of CDDP for 48 h. Cell lysates were analyzed 
for expressions of PARP (113 kD), cleaved PARP, phosphorylated Akt, total Akt, CD9, 
and calretinin by immunoblotting. (C) OS3-R5-CD9 cells were transfected with siRNAs 
against calretinin or control RNAs and cultured in low-serum conditions for 48 h. Cell 
lysates were analyzed for expressions of phosphorylated Akt, total Akt, and calretinin 
by immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 calretinin was almost absent in the parent, mock transfectant, and
NAG-2 transfectant in immunoblotting, whereas calretinin was ob-
viously present in three independent CD9 transfectants and its level
was parallel to that of CD9. We further examined if CD9 and calretinin
are co-expressed in a panel of lung tumor cell line ( Fig. 2 B). Consis-
tent with our previous report that most SCLC cells lack CD9 [ 8 ], ﬁve of
eight SCLC lines revealed no transcription and one cell line (OS2-RA)
showed only marginal transcription of CD9 gene. The other two lines
(OS1 and NCI-H209) clearly expressed CD9, and these CD9 ( + ) lines
also expressed calretinin. Meanwhile, all three NSCLC lines were CD9
( + ), but none of them expressed calretinin ( Fig. 2 B). 
CD9 was next deleted by knockdown with siRNA in the SCLC line
OS1, which expresses endogenous CD9. As shown in Fig. 2 C, left col-
umn , the knockdown of CD9 suppressed the level of calretinin. In anadditional experiment, we have studied CD9 and calretinin expres-
sions in multiple pleural mesothelioma cell lines and found that only
NCI-H226 expresses both CD9 and calretinin in immunoblotting ( Fig.
S1 ). CD9 was knocked down in this mesothelioma line, but unlike
OS1, the calretinin level was not affected ( Fig. 2 C, right column ). Our
recent report showed that endogenous CD9 is induced when the CD9
( −) SCLC line SBC-3 is exposed to an anticancer drug, cisplatin [ 10 ].
As shown in Fig. 2 D, calretinin was co-induced with endogenous CD9
in the cisplatin-exposed SBC-3 cells. 
We further investigated if CD9 is generally required for the ex-
pression of calretinin using tissues from wild-type and CD9 KO mice.
Calretinin was expressed in liver and brain lysates of wild-type mice,
and its levels were not affected by the loss of CD9, as evidenced by
abundant expression of calretinin in the lysates from CD9 KO mice
( Fig. S2 ). Together, regulation of calretinin expression by CD9 seemed
to be speciﬁc to human SCLC cells. 
3.3. CD9 is not physically associated with calretinin 
To investigate co-expressions of CD9 and calretinin in vivo , a tissue
microarray of SCLC was analyzed by immunohistochemistry. Among
30 patients, 11 were CD9 ( + ), 11 were calretinin ( + ), and 7 were
double-positive, and association between CD9 expression and calre-
tinin expression was weakly signiﬁcant ( Fig. 3 A, table ). Higher positive
rate of CD9 (11 / 30) in SCLC tissues compared with that in SCLC cell
lines [ 8 ] might be because some biopsy specimens were obtained
from relapsed or metastatic lesions, which were more frequently CD9
( + ) than pretreated primary tumors [ 10 ]. Representative staining of
CD9 and calretinin in a double-positive specimen indicated that ex-
pression patterns of these proteins were different ( Fig. 3 A). CD9 was
stained at the cell periphery, whereas calretinin showed nuclear and
cytoplasmic staining ( Fig. 3 A, insets ). Tetraspanins including CD9 are
characterized by their propensity to form multiprotein complexes at
the plasma membrane. To examine if calretinin is present in large pro-
tein complexes including CD9, co-precipitated proteins with CD9 was
immunoblotted with anti-calretinin Ab. As shown in Fig. 3 B, calretinin
did not co-precipitate with CD9 in OS3-R5-CD9 cell lysate even using
non-stringent detergent, Brij 99. Thus, calretinin was not present in
the protein complex including CD9. 
3.4. Calretinin promotes apoptosis of CD9 ( + ) SCLC cells 
Our previous reports have shown that ectopic expression of CD9
increases apoptosis by attenuation of postadhesive phosphorylation
of Akt [ 9 ] and that anticancer drugs induce endogenous CD9 in SCLC
cell lines [ 10 ]. To examine the involvement of calretinin in apopto-
sis of SCLC cells, calretinin was knocked down with siRNA in CD9
( + ) / calretinin ( + ) OS1 cells, and expression of PARP was exam-
ined as an indicator of apoptotic cell death [ 14 ]. Exposure of OS1
cells to 5 μM cisplatin increased endogenous CD9 and calretinin and
enhanced apoptosis as evidenced by decrease of 113-kD PARP and
decreased phosphorylation of Akt ( Fig. 4 A, control RNA). Knockdown
of calretinin prevented the OS1 apoptosis regardless of the exposure
to cisplatin ( Fig. 4 A, calretinin siRNA). It appeared that the calretinin
knockdown slightly upregulated CD9; this might reﬂect an unknown
feedback mechanism. Proapoptotic role of calretinin was also studied
in OS3-R5 cells. The exposure to CDDP for only 48 h did not induce
endogenous CD9 and calretinin in this cell line and, when compared
with the parent cells, OS3-R5-CD9 cells expressing calretinin revealed
higher sensitivity to CDDP, as evidenced by enhanced PARP cleavage
and decreased Akt phosphorylation ( Fig. 4 B). After the exposure to
1 μM CDDP for 48 h, viable cells of OS3-R5 and OS3-R5-CD9 were
56.1 ± 1.8% and 20.1 ± 2.7%, respectively ( P < 0.01). As shown in
Fig. 4 C, the knockdown of calretinin in OS3-R5-CD9 increased phos-
phorylation of Akt. These results suggest that calretinin may be a
downstream mediator of apoptosis in CD9 ( + ) SCLC cells. 
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p. Discussion 
Our previous studies have proposed that the absence of 
etraspanin CD9 contributes to highly malignant phenotype of SCLC 
nd that CD9 may be a pivotal regulator of SCLC cell survival [ 8 –10 ]. 
n the present study using a proteomics-based approach, we iden- 
iﬁed calretinin as a possible mediator of CD9-induced apoptosis in 
CLC. Calretinin was present in CD9 ( + ) SCLC cell lines but not in CD9 
 −) SCLC lines and CD9 ( + ) NSCLC lines. Ectopic or CDDP-induced 
xpression of CD9 upregulated calretinin in SCLC lines. Knockdown 
f CD9 conversely down-regulated calretinin in an SCLC line but not 
n a mesothelima cell line. Furthermore, knockdown of calretinin in- 
reased Akt phosphorylation and decreased apoptosis in CD9 ( + ) / 
alretinin ( + ) SCLC cell lines. Although statistical signiﬁcance in the 
ssociation of CD9 and calretinin expressions was weak ( P = 0.047) 
n SCLC tissues, we speculate that this might be due to elimination of 
poptotic CD9 ( + ) / calretinin ( + ) tumor cells in vivo . 
Calretinin is a member of the calcium-binding protein EF-hand 
amily ﬁrst identiﬁed in the retina. Calcium-binding proteins includ- 
ng calretinin are expressed in neuronal subpopulations of the ner- 
ous system. Calretinin is involved in cellular functions including 
ntracellular calcium buffering, messenger targeting, and the mod- 
lation of neuronal excitability. Modulation of calcium signaling by 
alretinin is important for timing and plasticity of synaptic events 
n neuronal networks. Some studies have suggested neuroprotective 
ole of calretinin against calcium-induced cytotoxicity, whereas oth- 
rs reported opposite effects [ 15 , 16 ]. Of note, a recent report using 
olorectal cancer cells indicated that calretinin is induced following 
reatment with oxaliplatin or 5-FU and positively regulates apoptotic 
ignals via as yet unknown mechanisms [ 14 ]. In line with this report, 
he present study suggested that calretinin mediates proapoptotic sig- 
aling in SCLC cells and for the ﬁrst time showed that CD9 positively 
egulates the expression of calretinin. It has been established that 
etraspanins including CD9 work as organizer of multiprotein com- 
lexes at the membrane [ 4 , 5 ]. Although calretinin has been reported 
o concentrate beneath the plasma membrane during maturation in 
eurons [ 17 ], it did not co-precipitate with CD9 in OS3-R5-CD9 cells, 
uggesting the presence of other mediators linking CD9 to enhanced 
xpression of calretinin. 
In conclusion, by proteomics-based approach, we have proposed 
 novel proapoptotic pathway that links the metastatic suppressor 
D9 to the neuronal calcium-binding protein, calretinin, in SCLC. In- 
uction of CD9 / calretinin may at least partially account for its high 
ensitivity to chemotherapy and might provide clues to new thera- 
eutic approach to suppress early growth, metastasis, and recurrence 
f SCLC. 
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